Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX), a company focused on developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral barrier indications, has announced its participation in the Sidoti August Virtual Investor Conference on August 14-15, 2024. CEO Gerald W. Bruce and CFO Vinay Shah will represent the company.

Key points:

• Bruce will present on August 14th at 2:30 PM (ET)
• The presentation will be accessible live via a provided link
• Virpax will host one-on-one meetings with investors on both conference days
• Registration for the event is free and open to all, not to Sidoti clients

This conference provides an opportunity for Virpax to showcase its innovative product pipeline and engage with potential investors.

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax^® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that Gerald W. Bruce, CEO, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 14-15, 2024. Joining him will be Vinay Shah, CFO.

The presentation will begin at 2:30 PM (ET) on Wednesday, August 14^th, and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_BEdsmtAvSLKxmX8cn7Uv7g. Virpax will also host virtual one-on-ones with investors on Wednesday and Thursday, August 14-15, 2024. To register for the presentation or one-on-ones, visit www.sidoti.com/events. Registration is free and you don't need to be a Sidoti client.

About Sidoti Events, LLC (“Events”) and Sidoti & Company, LLC (“Sidoti”)

In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti’s coverage universe comprises approximately 160 equities, of which 50 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti’s small- and microcap-focused nationwide sales force, which has connections with approximately 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808988879/en/

Investors Relations:

Betsy Brod

Affinity Growth Advisors

betsy.brod@affinitygrowth.com

(212) 661-2231

Source: Virpax Pharmaceuticals

FAQ

When is Virpax Pharmaceuticals (VRPX) presenting at the Sidoti Virtual Investor Conference?

Virpax Pharmaceuticals (VRPX) is presenting at the Sidoti Virtual Investor Conference on Wednesday, August 14, 2024, at 2:30 PM (ET).

Who will be representing Virpax Pharmaceuticals (VRPX) at the Sidoti conference?

Gerald W. Bruce, CEO, and Vinay Shah, CFO, will be representing Virpax Pharmaceuticals (VRPX) at the Sidoti Virtual Investor Conference.

What types of products does Virpax Pharmaceuticals (VRPX) develop?

Virpax Pharmaceuticals (VRPX) develops non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders, and anti-viral barrier indications.

How can investors participate in one-on-one meetings with Virpax Pharmaceuticals (VRPX)?

Investors can register for one-on-one meetings with Virpax Pharmaceuticals (VRPX) on August 14-15, 2024, by visiting www.sidoti.com/events. Registration is free and open to all.

Is there a cost to attend Virpax Pharmaceuticals' (VRPX) presentation at the Sidoti conference?

No, there is no cost to attend Virpax Pharmaceuticals' (VRPX) presentation at the Sidoti Virtual Investor Conference. Registration is free and open to all, not just Sidoti clients.